InvestorsHub Logo
Followers 50
Posts 2384
Boards Moderated 0
Alias Born 02/21/2016

Re: Dyno89 post# 177754

Wednesday, 05/24/2023 7:36:55 AM

Wednesday, May 24, 2023 7:36:55 AM

Post# of 198021
If you go to the BioClonetics website you will clearly see the company plans to use the clone 3 methodology for many diseases.

Thus, for the patient, the Clone 3 antibody immunotherapy will be remarkably different -- it will be safer, provide a much needed immunotherapeutic cure rather than requiring lifelong treatment, and costs substantially less than current ARV therapy.

The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria. As a part of our mission, the Company is testing these antibodies to prepare them for use as therapies and vaccines against these diseases.